TOCILIZUMAB for GIANT CELL ARTERITIS: BASELINE and TWELVE MONTH AUDIT DATA from the UK BRISTOL and BATH MULTIDISCIPLINARY MEETING

Authors
Category Primary study
JournalAnnals of the Rheumatic Diseases
Year 2022
This article has no abstract
Epistemonikos ID: 6737c58dfeb98729fdb91247d4145f1127e8c0e6
First added on: Feb 15, 2025